- |||||||||| Prolia (denosumab) / Amgen
Journal, HEOR: Comparative effectiveness of Denosumab vs alendronate among postmenopausal women with osteoporosis. (Pubmed Central) - May 16, 2024 In this cohort of almost half-a-million treatment-naive women with PMO, we observed clinically significant reductions in the risk of MOP, hip, NV, NHNV, and HV fractures for patients on denosumab compared with alendronate. Patients who remained on denosumab for longer periods of time experienced greater reductions in fracture risk.
- |||||||||| Prolia (denosumab) / Amgen
Review, Journal: Links among Obesity, Type 2 Diabetes Mellitus, and Osteoporosis: Bone as a Target. (Pubmed Central) - May 11, 2024 Bisphosphonates and denosumab significantly reduced the risk of vertebral fractures in patients with both obesity and T2DM...It is important to recognize elevated fracture risk and osteoporosis in obese and T2DM patients, as they are currently considered low risk and tend to be underdiagnosed and undertreated. The implementation of better diagnostic tools, including trabecular bone score, lumbar spine BMD/body mass index (BMI) ratio, and microRNAs to predict bone fragility, could improve fracture prevention in this patient group.
- |||||||||| Prolia (denosumab) / Amgen
Review, Journal: Modern treatment of unicameral and aneurysmatic bone cysts. (Pubmed Central) - May 10, 2024 The historical treatment with intraosseous injection of methylprednisolone acetate into the bone cysts nowadays is reduced due to the morbidity of multiple injections and the risk of multiple pathologic fractures until the healing...Further studies are needed to confirm the effectiveness of denosumab and its side effects on skeletally immature patients...For simple bone cysts, the combination of curettage, bone graft, and ESIN showed the best results. Sclerotherapy for ABC also shows promising results.
- |||||||||| Prolia (denosumab) / Amgen
Denosumab-Induced Severe Hypocalcemia with Recurrent Side Effects (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_1652; Denosumab-induced hypocalcemia is rare, but due to its severe effects on neuromuscular and cardiac function, patients should be counseled on the symptoms of hypocalcemia to ensure prompt medical evaluation. Ultimately, treatment for post-LTx osteoporosis should be individualized with consideration of specific medical history as well as routine monitoring of calcium levels when prescribed denosumab.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective. (Pubmed Central) - May 6, 2024 Of particular note, clinical and preclinical studies suggest that commonly prescribed osteoporosis drugs like bisphosphonates, intermittent parathyroid hormone, anti-sclerostin antibody, selective estrogen receptor modulators and anti-receptor activator of nuclear factor-kappa B ligand inhibitor denosumab may also relieve back pain. Here, we cite clinical and preclinical studies and include unpublished data to support the argument that a subset of these therapeutics for osteoporosis may alleviate low back pain by also targeting the IVD.
- |||||||||| zamaporvint (RXC004) / Redx
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: PORCUPINE: A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) (clinicaltrials.gov) - May 3, 2024 P2, N=25, Completed, Treatment of osteoporosis with denosumab was also simulated to conclude that the drug is not very effective if started before 10 years after menopause or before age 60. Recruiting --> Completed | N=50 --> 25 | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Aug 2023 --> Apr 2024
- |||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Journal: 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. (Pubmed Central) - May 2, 2024 3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
- |||||||||| Prolia (denosumab) / Amgen
Trial termination, Metastases: SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) - Apr 25, 2024 P3, N=595, Terminated, Completed --> Terminated; Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a benefit for denosumab could be shown, these results would be of very limited clinical impact by the time they would be available
- |||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Retrospective data, Journal: The sequential antifracturative treatment: a meta-analysis of randomized clinical trials. (Pubmed Central) - Apr 24, 2024 In general, at 2?years after the switch from anabolic to antiresorptive drugs, a weighted BMD was increased at the lumbar spine, total hip, and femoral neck site. The Task Force formulated recommendations on sequential therapy, which is the first treatment with anabolic drugs or 'bone builders' in patients with very high or imminent risk of fracture.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Bone loss after discontinuation of denosumab: the devil is in the details. (Pubmed Central) - Apr 21, 2024 Bone turnover markers were appropriately suppressed and bone mineral density increased in the spine and hip. This case illustrates how the overshooting phenomenon following denosumab discontinuation may be compounded by the development of secondary conditions, which can result in suboptimal response to antiresorptive osteoporosis medications.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Denosumab-induced bone changes in a child: a case report. (Pubmed Central) - Apr 20, 2024 This case illustrates how the overshooting phenomenon following denosumab discontinuation may be compounded by the development of secondary conditions, which can result in suboptimal response to antiresorptive osteoporosis medications. We present the case of a 9-year-old girl who developed striking bone changes following two years of denosumab therapy for giant cell lesions of the jaw.
- |||||||||| Prolia (denosumab) / Amgen
Review, Journal: Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review. (Pubmed Central) - Apr 13, 2024 Physicians and dentists should provide comprehensive information to patients prescribed with antiresorptive drugs, emphasizing the need for an awareness of the risks of MRONJ in the context of osseointegrated implants. A longer term of follow-up is recommended to identify and manage MRONJ around dental implants in an early manner.
- |||||||||| Prolia (denosumab) / Amgen
Embolization of huge giant cell tumor () - Apr 10, 2024 - Abstract #ECIO2024ECIO_479; However, the drug caused mandibular osteonecrosis, necessitating treatment withdrawal. Due to the location, size, and marked vascularity, embolization was chosen as therapeutic option.
|